Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

David H Wagner Jr.

TitleAssociate Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-WW Ctr General Operations
Phone303/724-4787

    Collapse Research 
    Collapse research activities and funding
    R01DK131196     (WAGNER, DAVID H.)Mar 10, 2022 - Feb 28, 2026
    NIH
    Discovering the Mechanism of Action of a peptide drug, OPT101, that targets CD40 mediated inflammation in type 1 diabetes
    Role: Principal Investigator
    R42DK115296     (WAGNER, DAVID H.)Aug 1, 2017 - Aug 31, 2021
    NIH
    Development of a Clinical Screening Platform for Type 1 Diabetes
    Role: Principal Investigator
    R41AI129571     (WAGNER, DAVID H.)Aug 1, 2017 - Jul 31, 2019
    NIH
    Screening for the autoimmune component of multiple sclerosis
    Role: Principal Investigator
    R42AI131784     (WAGNER, DAVID H.)Feb 15, 2017 - Nov 30, 2021
    NIH
    Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes
    Role: Principal Investigator
    R41AI131784     (WAGNER, DAVID H.)Feb 15, 2017 - Dec 19, 2018
    NIH
    Developing a small peptide to control autoimmune inflammation in type 1 diabetes
    Role: Principal Investigator
    R41AI113977     (WAGNER, DAVID H)Jun 15, 2014 - May 31, 2017
    NIH
    Developing a new treatment for MS: Controlling CD40 in EAE
    Role: Principal Investigator
    R21AI106011     (WAGNER, DAVID H.)Aug 7, 2013 - Jul 31, 2015
    NIH
    A unique approach to control the CD40/CD154 inflammatory axis in type 1 diabetes
    Role: Principal Investigator
    R01DK075013     (WAGNER, DAVID H)Aug 1, 2007 - Apr 30, 2013
    NIH
    CD40-Induced TCR Revision: A Mechanism for Autoimmunity
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Frank FM, Wagner DH, Postan M, Petray PB. Importance of CD40/CD40 dyad in the course of infection with Trypanosoma cruzi: Impact of its inhibition. Microb Pathog. 2023 Oct; 183:106327. PMID: 37640275.
      View in: PubMed
    2. Vaitaitis GM, Wagner DH. Modulating CD40 and integrin signaling in the proinflammatory nexus using a 15-amino-acid peptide, KGYY15. J Biol Chem. 2023 05; 299(5):104625. PMID: 36944397.
      View in: PubMed
    3. Curran C, Vaitaitis G, Waid D, Volmer T, Alverez E, Wagner DH. Ocrevus reduces TH40 cells, a biomarker of systemic inflammation, in relapsing multiple sclerosis (RMS) and in progressive multiple sclerosis (PMS). J Neuroimmunol. 2023 Jan 15; 374:578008. PMID: 36535240.
      View in: PubMed
    4. Okeke NL, McLaurin T, Gilliam-Phillips R, Wagner DH, Barnwell VJ, Johnson YM, James O, Webb PB, Parker SD, Hill B, McKellar MS, Mitchell JT. Awareness and acceptability of HIV pre-exposure prophylaxis (PrEP) among students at two historically Black universities (HBCU): a cross-sectional survey. BMC Public Health. 2021 05 19; 21(1):943. PMID: 34006245.
      View in: PubMed
    5. Vaitaitis GM, Rihanek M, Alkanani AK, Waid DM, Gottlieb PA, Wagner DH. Biomarker Discovery in Pre-Type 1 Diabetes; Th40 Cells as a Predictive Risk Factor. J Clin Endocrinol Metab. 2019 Sep 01; 104(9):4127-4142. PMID: 31063181.
      View in: PubMed
    6. Vaitaitis GM, Olmstead MH, Waid DM, Carter JR, Wagner DH. CD40-targeted peptide proposed for type 1 diabetes therapy lacks relevant binding affinity to its cognate receptor. Reply to Pagni PP, Wolf A, Lo Conte M et al [letter]. Diabetologia. 2019 09; 62(9):1730-1731. PMID: 31286154.
      View in: PubMed
    7. Vaitaitis GM, Yussman MG, Wagner DH. A CD40 targeting peptide prevents severe symptoms in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2019 07 15; 332:8-15. PMID: 30925295.
      View in: PubMed
    8. Vaitaitis GM, Wagner DH. Are we aiming to miss in translational autoimmunity treatments? F1000Res. 2018; 7:1754. PMID: 30542620.
      View in: PubMed
    9. Bleich D, Wagner DH. Challenges to Reshape the Future of Type 1 Diabetes Research. J Clin Endocrinol Metab. 2018 08 01; 103(8):2838-2842. PMID: 29912401.
      View in: PubMed
    10. Wagner DH. Overlooked Mechanisms in Type 1 Diabetes Etiology: How Unique Costimulatory Molecules Contribute to Diabetogenesis. Front Endocrinol (Lausanne). 2017; 8:208. PMID: 28878738.
      View in: PubMed
    11. Vaitaitis GM, Waid DM, Yussman MG, Wagner DH. CD40-mediated signalling influences trafficking, T-cell receptor expression, and T-cell pathogenesis, in the NOD model of type 1 diabetes. Immunology. 2017 10; 152(2):243-254. PMID: 28542921.
      View in: PubMed
    12. Vaitaitis GM, Yussman MG, Waid DM, Wagner DH. Th40 cells (CD4+CD40+ Tcells) drive a more severe form of Experimental Autoimmune Encephalomyelitis than conventional CD4 T cells. PLoS One. 2017; 12(2):e0172037. PMID: 28192476.
      View in: PubMed
    13. Vaitaitis GM, Olmstead MH, Waid DM, Carter JR, Wagner DH. A CD40-targeted peptide controls and reverses type 1 diabetes in NOD mice. Diabetologia. 2014 Nov; 57(11):2366-73. PMID: 25104468.
      View in: PubMed
    14. Deng G, Carter J, Traystman RJ, Wagner DH, Herson PS. Pro-inflammatory T-lymphocytes rapidly infiltrate into the brain and contribute to neuronal injury following cardiac arrest and cardiopulmonary resuscitation. J Neuroimmunol. 2014 Sep 15; 274(1-2):132-40. PMID: 25084739.
      View in: PubMed
    15. Waid DM, Schreiner T, Vaitaitis G, Carter JR, Corboy JR, Wagner DH. Defining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells. J Neuroimmunol. 2014 May 15; 270(1-2):75-85. PMID: 24690203.
      View in: PubMed
    16. Vaitaitis GM, Wagner DH. CD40 interacts directly with RAG1 and RAG2 in autoaggressive T cells and Fas prevents CD40-induced RAG expression. Cell Mol Immunol. 2013 Nov; 10(6):483-9. PMID: 24037181.
      View in: PubMed
    17. Vaitaitis GM, Carter JR, Waid DM, Olmstead MH, Wagner DH. An alternative role for Foxp3 as an effector T cell regulator controlled through CD40. J Immunol. 2013 Jul 15; 191(2):717-25. PMID: 23776180.
      View in: PubMed
    18. Chow K, Fessel JP, Schmidt EP, Gaskill C, Alvarez D, Graham B, Harrison DG, Wagner DH, Nozik-Grayck E, West JD, Klemm DJ, Majka SM. Dysfunctional resident lung mesenchymal stem cells contribute to pulmonary microvascular remodeling. Pulm Circ. 2013 Jan; 3(1):31-49. PMID: 23662173.
      View in: PubMed
    19. Wagner DH. The specific antigen approach in multiple sclerosis: can it ever be enough? Clin Immunol. 2012 Aug; 144(2):139-41. PMID: 22729132.
      View in: PubMed
    20. Vaitaitis GM, Wagner DH. Galectin-9 controls CD40 signaling through a Tim-3 independent mechanism and redirects the cytokine profile of pathogenic T cells in autoimmunity. PLoS One. 2012; 7(6):e38708. PMID: 22685601.
      View in: PubMed
    21. Carter J, Vaitaitis GM, Waid DM, Wagner DH. CD40 engagement of CD4+ CD40+ T cells in a neo-self antigen disease model ablates CTLA-4 expression and indirectly impacts tolerance. Eur J Immunol. 2012 Feb; 42(2):424-35. PMID: 22105491.
      View in: PubMed
    22. Chow KS, Jun D, Helm KM, Wagner DH, Majka SM. Isolation & characterization of Hoechst(low) CD45(negative) mouse lung mesenchymal stem cells. J Vis Exp. 2011 Oct 26; (56):e3159. PMID: 22064472.
      View in: PubMed
    23. Jun D, Garat C, West J, Thorn N, Chow K, Cleaver T, Sullivan T, Torchia EC, Childs C, Shade T, Tadjali M, Lara A, Nozik-Grayck E, Malkoski S, Sorrentino B, Meyrick B, Klemm D, Rojas M, Wagner DH, Majka SM. The pathology of bleomycin-induced fibrosis is associated with loss of resident lung mesenchymal stem cells that regulate effector T-cell proliferation. Stem Cells. 2011 Apr; 29(4):725-35. PMID: 21312316.
      View in: PubMed
    24. Vaitaitis GM, Wagner DH. CD40 glycoforms and TNF-receptors 1 and 2 in the formation of CD40 receptor(s) in autoimmunity. Mol Immunol. 2010 Aug; 47(14):2303-13. PMID: 20646763.
      View in: PubMed
    25. Baker RL, Wagner DH, Haskins K. CD40 on NOD CD4 T cells contributes to their activation and pathogenicity. J Autoimmun. 2008 Dec; 31(4):385-92. PMID: 18951762.
      View in: PubMed
    26. Waid DM, Vaitaitis GM, Pennock ND, Wagner DH. Disruption of the homeostatic balance between autoaggressive (CD4+CD40+) and regulatory (CD4+CD25+FoxP3+) T cells promotes diabetes. J Leukoc Biol. 2008 Aug; 84(2):431-9. PMID: 18469093.
      View in: PubMed
    27. Vaitaitis GM, Wagner DH. High distribution of CD40 and TRAF2 in Th40 T cell rafts leads to preferential survival of this auto-aggressive population in autoimmunity. PLoS One. 2008 Apr 30; 3(4):e2076. PMID: 18446238.
      View in: PubMed
    28. Siebert JC, Inokuma M, Waid DM, Pennock ND, Vaitaitis GM, Disis ML, Dunne JF, Wagner DH, Maecker HT. An analytical workflow for investigating cytokine profiles. Cytometry A. 2008 Apr; 73(4):289-98. PMID: 18163472.
      View in: PubMed
    29. Waid DM, Wagner RJ, Putnam A, Vaitaitis GM, Pennock ND, Calverley DC, Gottlieb P, Wagner DH. A unique T cell subset described as CD4loCD40+ T cells (TCD40) in human type 1 diabetes. Clin Immunol. 2007 Aug; 124(2):138-48. PMID: 17560173.
      View in: PubMed
    30. Wagner DH. Re-shaping the T cell repertoire: TCR editing and TCR revision for good and for bad. Clin Immunol. 2007 Apr; 123(1):1-6. PMID: 16990051.
      View in: PubMed
    31. Waid DM, Vaitaitis GM, Wagner DH. Peripheral CD4loCD40+ auto-aggressive T cell expansion during insulin-dependent diabetes mellitus. Eur J Immunol. 2004 May; 34(5):1488-97. PMID: 15114683.
      View in: PubMed
    32. Vaitaitis GM, Poulin M, Sanderson RJ, Haskins K, Wagner DH. Cutting edge: CD40-induced expression of recombination activating gene (RAG) 1 and RAG2: a mechanism for the generation of autoaggressive T cells in the periphery. J Immunol. 2003 Apr 01; 170(7):3455-9. PMID: 12646605.
      View in: PubMed
    33. Wagner DH, Vaitaitis G, Sanderson R, Poulin M, Dobbs C, Haskins K. Expression of CD40 identifies a unique pathogenic T cell population in type 1 diabetes. Proc Natl Acad Sci U S A. 2002 Mar 19; 99(6):3782-7. PMID: 11891296.
      View in: PubMed
    Wagner's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (172) concept(s)
    _
    Co-Authors Expand Description
    See all (11) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)